Table 3.

Multivariate analysis of CSS in PC patients.

Characteristics	HR (95% CI)	P value
Age (Reference: < 68)
68–79	1.259 (1.075–1.474)	0.004
> 79	1.460 (1.192–1.789)	< 0.001
Sex (Reference: Female)
Male	1.017 (0.872–1.186)	0.830
Race (Reference: Black)
White	0.756 (0.618–0.925)	0.007
Other	0.805 (0.627–1.034)	0.090
Tumor size (Reference: < 2.6)
2.6–3.5	1.175 (0.954–1.447)	0.130
> 3.5	1.223 (0.992–1.508)	0.060
Grade (Reference: Well differentiated)
Moderately differentiated	1.823 (1.336–2.488)	< 0.001
Poorly differentiated	2.231 (1.574–3.162)	< 0.001
Undifferentiated	2.284 (0.838–6.222)	0.110
Unknown	1.980 (1.445–2.714)	< 0.001
Radiotherapy (Reference: None/Unknown)
Yes	1.089 (0.915–1.297)	0.340
Chemotherapy (Reference: None/Unknown)
Yes	0.570 (0.481–0.676)	< 0.001
Surgery (Reference: None/Unknown)
Yes	0.441 (0.348–0.559)	< 0.001
AJCC T status (Reference: T1)
T2	1.607 (1.028–2.513)	0.037
T3	1.888 (1.221–2.919)	0.004
T4	1.665 (1.050–2.639)	0.030
Unknown	2.607 (1.579–4.303)	< 0.001
AJCC N status (Reference: N0)
N1	1.235 (1.065–1.433)	0.005
Unknown	1.383 (0.944–2.026)	0.096
AJCC M status (Reference: M0)
M1	1.866 (1.568–2.221)	< 0.001
Primary site (Reference: Head of pancreas)
Body of pancreas	0.861 (0.700–1.059)	0.160
Tail of pancreas	0.903 (0.720–1.133)	0.380
Pancreatic duct	1.438 (0.986–2.098)	0.059
Other specified parts of pancreas	0.958 (0.741–1.238)	0.740
Overlapping lesion of pancreas	1.069 (0.812–1.407)	0.640
Pancreas, NOS	0.864 (0.583–1.280)	0.470
Histological subtype (Reference: Adenocarcinoma)
Infiltrating duct carcinoma	1.288 (1.061–1.564)	0.011
Neuroendocrine carcinoma	0.195 (0.130–0.292)	< 0.001
Other	0.640 (0.476–0.860)	0.003
Prior thyroid cancer history (Reference: without)
With	0.722 (0.542–0.961)	0.026

CSS cancer-specific survival, AJCC American Joint Commission on Cancer(7th), SEER the surveillance, epidemiology, and end results, HR hazard ratio, CI confidence interval.